Cervarix®

BIOLOGICAL4 trials

Sponsors

GlaxoSmithKline, Murdoch Childrens Research Institute, CHU de Reims

Conditions

Anogenital WartsCervical CancerInfections, MeningococcalInfections, Papillomavirus

Phase 3

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

CompletedNCT01755689

GlaxoSmithKlineInfections, Meningococcal

Start: 2013-01-11End: 2014-04-29Updated: 2018-07-03

Phase 4

Comparing Health Services Interventions for the Prevention of HPV-related Cancer

CompletedNCT02837926

CHU de ReimsCervical Cancer

Start: 2016-05-31End: 2018-06-30Updated: 2019-04-10

Unknown Phase

Drug Use Investigation for Cervarix®

CompletedNCT01187927

GlaxoSmithKlineInfections, Papillomavirus

Start: 2010-09-30End: 2014-01-31Updated: 2015-01-26

Evaluation of Long Term Immunity Following HPV Vaccination

CompletedNCT02276521

Murdoch Childrens Research InstituteAnogenital Warts, Cervical Cancer

Start: 2015-02-28End: 2015-03-31Updated: 2015-09-23

Related Papers

MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16/18 in girls and young women: Results from a phase III randomized trial

Vaccine2018-05-199 citations